Genetic Immunity is a privately held clinical-stage biotech firm that concentrates on the discovery, development, and commercialization of “Immune Therapies” for treating chronic viral infections, allergies, and cancer. Immune Therapies are designed to boost and intensify certain immune response to control or modify these currently incurable diseases. The company is confident that its products will help individuals live healthier, longer, and better lives.
Genetic Immunity developed a proprietary Vaccine Platform with “a given disease’s antigen specific plasmid DNA (pDNA), a nanomedicine formulation which encapsulates the pDNA to make it closely resemble a virus (we call this combination a nanoparticle), a topical (through the skin) administration device we call DermaPrep which delivers the vaccine via dendritic cell to lymph nodes of the immune system, and a software product which allows us to design antigen specific pDNA and closely match it to a patient’s genetic and HLA profile.” The mixture of those technologies encourages the cost-effective and quick creation of new biologic vaccine products.
Its Lead Therapeutic candidate vaccine is intended to treat HIV. Called “DermaVir,” it efficiently boosts immune response, which produces a killer cell that kills HIV-infected cells. Its three human clinical trials—Phase I, Phase I/II, and Phase II—have proven its HIV vaccine can kill HIV-infected cells. DermaVir has an excellent safety profile comparable to placebo. The goal is to offer DermaVir as a co-treatment alternative to antiretroviral therapy (ART) and after more clinical trial, to show effectiveness to ART-resistant patients.
Aside from HIV, the group is also working on an extensive pipeline of product candidates, including therapeutic treatments for cancer, allergies, MAGE, the human papillomavirus, etc.